Fig. 3

In vitro antitumor effect of LA-CMGL. (a) Viability of HepG2 cells treated with different dose levels of CPT for 24 h (n = 3). (b) Viability of HepG2 cells incubated with CPT, miR-145, CPT + miR-145 from 12 to 60 h (n = 3). (c) The proliferation inhibition of HepG2 cells and HepaRG cells treated with different formulations (G1-7) with the final miR-145 concentration of 100 nM and CPT concentration of 10 µg/mL. G1, G2, G3, G4, G5, G6 and G7 represented PBS, LA-NC-L, LA-CPT-L, LA-miR-145-L, LA-CMGL, CMGL and CPT + miR-145 groups, respectively (n = 3). (d) Flow cytometry analysis of the apoptosis ratios in HepG2 cells treated with different formulations (n = 3). (e) WB analysis showed LA-CMGL significantly increased the expression of C-caspase3 and Cyt-c protein. β-actin was used as an internal control. (f) In vitro wound scratch assay of the HepG2 cells (n = 3). Quantitative analysis was performed using Image J software (n = 3). Data are mean ± standard deviation (SD). Statistical significances in (a), (c), (e) and (f) were calculated via the Student’s t test (***p < 0.001). Statistical significances in (b) were calculated via the one-way ANOVA with Tukey’s post hoc test (***p < 0.001)